Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Long-Term Debt Repayments (2016)

Integra Lifesciences Holdings' Long-Term Debt Repayments history spans 4 years, with the latest figure at $166000.0 for Q4 2016.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $166000.0 in Q4 2016 year-over-year; TTM through Sep 2017 was $166000.0, a 65.91% decrease, with the full-year FY2025 number at $575.0 million, changed N/A from a year prior.
  • Long-Term Debt Repayments hit $166000.0 in Q4 2016 for Integra Lifesciences Holdings, up from $164000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for IART hit a ceiling of $2.1 million in Q3 2015 and a floor of -$370000.0 in Q4 2014.
  • Historically, Long-Term Debt Repayments has averaged $288363.6 across 3 years, with a median of $163000.0 in 2016.
  • Biggest five-year swings in Long-Term Debt Repayments: skyrocketed 1598.4% in 2015 and later plummeted 92.28% in 2016.
  • Tracing IART's Long-Term Debt Repayments over 3 years: stood at -$370000.0 in 2014, then soared by 673.78% to $2.1 million in 2015, then tumbled by 92.18% to $166000.0 in 2016.
  • Business Quant data shows Long-Term Debt Repayments for IART at $166000.0 in Q4 2016, $164000.0 in Q3 2016, and $163000.0 in Q2 2016.